miR-770-5p regulates KDM5B and links its nuclear localization to HER2 signaling in trastuzumab-resistant breast cancer
- 20 July 2026
- journal article
- research article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (9) , 4181-4196
Abstract
Therapeutic resistance to trastuzumab remains a critical limitation in the management of HER2-positive (HER2+) breast cancer. Emerging evidence implicates epigenetic regulators, including microRNAs and histone demethylases, in modulating HER2 signaling and drug responsiveness. This study aimed to investigate the mechanistic role of miR-770-5p and its interplay with KDM5B in the context of trastuzumab resistance. An integrative approach combining in silico analyses with in vitro functional assays was employed in trastuzumab-sensitive and -resistant HER2 + breast cancer cell lines. Molecular, subcellular, and phenotypic effects of miR-770-5p modulation were assessed using qRT-PCR, Western blotting, immunofluorescence, RNA-FISH, luciferase reporter assays, and live-cell imaging. KDM5B was significantly overexpressed in HER2 + tumors and inversely correlated with HER2 expression. miR-770-5p directly targeted KDM5B and was associated with coordinated regulation of HER2 signaling at both transcription-associated and post-transcriptional levels. Overexpression of miR-770-5p was associated with reduced expression of KDM5B, TCF12, and GRB7, supporting the involvement of a KDM5B–TCF12–GRB7 regulatory network in HER2 modulation. Functionally, miR-770-5p reversed EMT-associated phenotypic features and enhanced trastuzumab sensitivity. Clinically, reduced KDM5B expression was associated with improved distant metastasis-free survival in ER+/HER2-high breast cancer patients. Collectively, miR-770-5p functions as a nuclear-associated regulatory microRNA that modulates HER2 signaling through epigenetic regulation of KDM5B and associated downstream networks. These findings suggest a previously unrecognized regulatory mechanism contributing to trastuzumab response and provide potential therapeutic avenues for HER2-positive breast cancer.Keywords
Funding Information
- Ankara University Scientific Research Projects Coordination Unit (Project number: TDS-2022-2401)
This publication has 65 references indexed in Scilit:
- MicroRNA-mediated autophagy and drug resistance in cancer: mechanisms and therapeutic strategiesDiscover Oncology, 2024
- Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategiesBiomedicine & Pharmacotherapy, 2024
- Lysine demethylase 5B (KDM5B): A key regulator of cancer drug resistanceJournal of Biochemical and Molecular Toxicology, 2023
- miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic reviewBiochemistry and Biophysics Reports, 2023
- Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancerThe Breast, 2022
- Dissecting the biological heterogeneity of HER2-positive breast cancerThe Breast, 2021
- ROCplot.org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti‐HER2 therapy using transcriptomic data of 3,104 breast cancer patientsInternational Journal of Cancer, 2019
- KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic ResistanceCancer Cell, 2018
- JARID1B Is a Luminal Lineage-Driving Oncogene in Breast CancerCancer Cell, 2014
- Breast cancer associated transcriptional repressor PLU‐1/JARID1B interacts directly with histone deacetylasesInternational Journal of Cancer, 2007